-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Biocryst Pharmaceuticals Inc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2021 to Q4 2024.
- Biocryst Pharmaceuticals Inc Income Tax Expense (Benefit) for the quarter ending December 31, 2024 was $804K.
- Biocryst Pharmaceuticals Inc Income Tax Expense (Benefit) for the twelve months ending December 31, 2024 was $1.93M, a 522% increase year-over-year.
- Biocryst Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2024 was $1.93M, a 522% increase from 2023.
- Biocryst Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2023 was $310K, a 88.7% decline from 2022.
- Biocryst Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2022 was $2.73M, a 21.3% increase from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)